ANNOVIS BIO
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About ANVS
Annovis Bio, Inc. is a late-stage clinical drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), and Parkinson’s disease (PD). The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.
Find out what a historical investment in ANNOVIS BIO would be worth today using our ANVS stock calculator.
$41.70M
-
0.00%
328.11K
$2.13
$1.96
$2.07
$17.88
$1.11
Ready to start your investing journey with Stake?
Open an accountANVS FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in ANVS
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in ANVS
on Stake
Buy ANVS from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of ANVS from only US$10 with fractional shares
